1415124-73-0

Basic information

• Product Name: methyl-3,5-difluoro-4-formyl benzoate
• CAS NO: 1415124-73-0
• Molecular Weight: 200.142
• Mol File: 1415124-73-0.mol
• Article Data: 4

Chemical Properties

• Boiling Point: 293.7±40.0 °C(Predicted)
• Density: 1.357±0.06 g/cm3(Predicted)
• CAS DataBase Reference: methyl-3,5-difluoro-4-formyl benzoate(CAS DataBase Reference)
• NIST Chemistry Reference: methyl-3,5-difluoro-4-formyl benzoate(1415124-73-0)
• EPA Substance Registry System: methyl-3,5-difluoro-4-formyl benzoate(1415124-73-0)

Safety Data

• Hazardous Substances Data: 1415124-73-0(Hazardous Substances Data)

Upstream product

• 736990-88-8 3,5-difluoro-4-formylbenzoic acid 
• 74-88-4 methyl iodide 
• 455-40-3 3,5-difluorobenzoic acid 
• 68-12-2 N,N-dimethyl-formamide 
• 216393-55-4 methyl 3,5-difluorobenzoate 

Downstream Products

• 1308849-85-5 3,5-difluoro-4-formyl-N-methylbenzamide 
• 1621165-26-1 tert-butyl (S)-2-((2-(2,6-difluoro-4-(methylcarbamoyl)phenyl)-7-methylimidazo[1,2-a]pyridine- 3-yl)methyl)morpholine-4-carboxylate 
• 1621164-77-9 (R)-tert-butyl 2-((2-(2,6-difluoro-4-(methylcarbamoyl)phenyl)-7-methylimidazo[1,2-a]pyridin-3-yl)methyl)morpholine-4-carboxylate 
• 1621164-74-6 methyl (S)-2-((2-(2,6-difluoro-4-(4-methylcarbamoyl)phenyl)-7-methylimidazo[1,2-a]pyridin-3-yl)methyl)morpholine-4-carboxylate 

Relevant articles and documents

IMIDAZOPYRIDINE COMPOUNDS AND USES THEREOF

This invention generally relates to substituted imidazopyridine compounds, particularly substituted 4-(imidazo[1,2-a]pyridin-2-yl)benzamide compounds and salts thereof. This invention also relates to pharmaceutical compositions and kits comprising such a compound, uses of such a compound (including, for example, treatment methods and medicament preparations), processes for making such a compound, and intermediates used in such processes.

HETEROCYCLIC COMPOUNDS AS PROTEIN KINASE INHIBITORS

The present invention provides a heterocyclic compound of formula (I), a pharmaceutically acceptable salt thereof, a prodrug thereof or a hydrate thereof, wherein A, A' B, D, R1, R2 and R3 are as defined herein, a pharmaceutical composition comprising a compound of formula (I) as an active ingredient, methods of production, and methods of use thereof. Particularly, the present invention provides a compound of formula (I) useful for treating or preventing a disease, condition or disorder associated with protein kinases, preferably Janus Kinase family.